These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 8485826)

  • 1. ACE inhibitors in early stages of heart failure.
    Riegger GA
    Circulation; 1993 May; 87(5 Suppl):IV117-9. PubMed ID: 8485826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Value of ACE inhibitors in heart failure (clinical aspects)].
    Riegger AJ
    Z Kardiol; 1992; 81 Suppl 4():93-6. PubMed ID: 1290309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Vasodilator agents in chronic heart failure: which is the best option?].
    Corbalán R; Kunstmann S; Jalil J
    Rev Med Chil; 1993 Jan; 121(1):81-8. PubMed ID: 8235172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Side effects of vasodilator therapy in heart failure: risk of hypotension with ACE inhibitors].
    Kromer EP; Elsner D; Riegger GA
    Z Kardiol; 1991; 80 Suppl 2():11-5. PubMed ID: 2024538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists in the treatment of heart failure caused by left ventricular systolic dysfunction.
    Sander GE; McKinnie JJ; Greenberg SS; Giles TD
    Prog Cardiovasc Dis; 1999; 41(4):265-300. PubMed ID: 10362349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppression of the renin-angiotensin-aldosterone system in chronic heart failure: choice of agents and clinical impact.
    Jorde UP
    Cardiol Rev; 2006; 14(2):81-7. PubMed ID: 16493245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The value of ACE inhibitors in heart failure (mechanism of action)].
    Drexler H
    Z Kardiol; 1992; 81 Suppl 4():85-91. PubMed ID: 1290308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ACE inhibitors in congestive heart failure.
    Kantner TR
    J Fam Pract; 1992 Sep; 35(3):305-14. PubMed ID: 1517728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The role of ACE-inhibition in the therapy of chronic heart insufficiency].
    Drexler H; Just H
    Wien Med Wochenschr; 1990 Jan; 140(1-2):40-5. PubMed ID: 2137955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing the treatment of congestive heart failure: diuretics, vasodilators, and angiotensin-converting enzyme inhibitors.
    Chow MS
    Pharmacotherapy; 1993; 13(5 Pt 2):82S-87S. PubMed ID: 8233997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Therapy of heart failure with ACE inhibitors--"evidence-based medicine" and clinical reality].
    Auer J; Berent R; Kirchgatterer A; Weber T; Mayr H; Maurer E; Eber B
    Wien Med Wochenschr; 1999; 149(21-22):587-92. PubMed ID: 10666823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapy of left ventricular dysfunction: implications of recent therapeutic trials and future directions for therapy.
    Pitt B
    Schweiz Med Wochenschr; 1993 Feb; 123(8):342-8. PubMed ID: 8095738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vasodilator therapy for congestive heart failure. Lessons from mortality trials.
    Groden DL
    Arch Intern Med; 1993 Feb; 153(4):445-54. PubMed ID: 8435024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Should cardiac insufficiency be first treated by angiotensin converting enzyme inhibitors?].
    Bareiss P; Roul G
    Arch Mal Coeur Vaiss; 1993 Feb; 86 Spec No 2():35-40. PubMed ID: 8215788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Congestive heart failure: new therapeutic strategies.
    Pitt B
    Clin Cardiol; 1992 Sep; 15 Suppl 1():I2-4. PubMed ID: 1395211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The evolving role of angiotensin-converting enzyme inhibition in heart failure: expanding the protective envelope.
    Teerlink JR
    J Cardiovasc Pharmacol; 1994; 24 Suppl 3():S32-7. PubMed ID: 7700062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The therapeutic role of RAS blockade in chronic heart failure.
    Werner CM; Böhm M
    Ther Adv Cardiovasc Dis; 2008 Jun; 2(3):167-77. PubMed ID: 19124420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Growth stimulating properties of angiotensin II on the heart: consequences for therapy of heart failure].
    Schunkert H; Holmer SR; Riegger G
    Z Kardiol; 1993; 82 Suppl 4():1-6. PubMed ID: 8147057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.